BPC-157 (Body Protection Compound-157) is a pentadecapeptide derived from human gastric juice
In clinical trials, people who took lower doses of semaglutide lost less weight than those who took higher doses
Individual results vary based on dose, adherence, starting weight, diet, activity, and individual biology
E-EL-R3007, Elabscience, Texas, USA), TGF-1 (Cat no
Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC
no clear plateau) Zepbound: ~20% to 22.5% (long-term studies) Glycemic Control (T2D): Retatrutide: HbA1c reduction up to ~2.0% (Phase III) Zepbound: Strong, well-established HbA1c reductions (~2.0% to 2.4%) across Phase III trials Durability of Effect: Retatrutide: Sustained weight loss with continued decline over time Zepbound: Durable, but tends to plateau earlier Safety & Tolerability: Retatrutide: Higher rates of GI side effects